Clinical trial
A Phase 2 Study of Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
NCT02294357 is registered in ClinicalTrials.gov with Oncotherapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
- Lead sponsor
- Oncotherapeutics
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- December 31, 2014
- Completion date
- September 22, 2020
- Enrollment
- 45 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.